AR116966A1 - CYCLINE-DEPENDENT KINASE INHIBITORS 7 (CDK7) - Google Patents
CYCLINE-DEPENDENT KINASE INHIBITORS 7 (CDK7)Info
- Publication number
- AR116966A1 AR116966A1 ARP190103205A ARP190103205A AR116966A1 AR 116966 A1 AR116966 A1 AR 116966A1 AR P190103205 A ARP190103205 A AR P190103205A AR P190103205 A ARP190103205 A AR P190103205A AR 116966 A1 AR116966 A1 AR 116966A1
- Authority
- AR
- Argentina
- Prior art keywords
- pharmaceutically acceptable
- cdk7
- dependent kinase
- dimethylpiperidin
- ethyl
- Prior art date
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Composiciones que incluyen compuestos de fórmula (1) o (1a), o formas de los mismos, y sales, solvatos (por ejemplo, hidratos) farmacéuticamente aceptables, estereoisómeros, tautómeros y formas isotópicas de los mismos. También, métodos (o usos) y kits, que incluyen los compuestos o formulaciones farmacéuticamente aceptables, para tratar o prevenir una enfermedad (por ejemplo, una enfermedad proliferativa) en un sujeto. La administración de un compuesto o composición farmacéutica según se describe puede inhibir la actividad aberrante de la quinasa dependiente de ciclina 7 (CDK7) y, por lo tanto, puede inducir la apoptosis celular en el sujeto. Reivindicación 1: Un compuesto que tiene la fórmula estructural (1), o una sal farmacéuticamente aceptable del mismo, en donde: R¹ es metilo o etilo; R² es metilo o etilo; R³ es 5-metilpiperidin-3-ilo, 5,5-dimetilpiperidin-3-ilo, 6-metilpiperdin-3-ilo, o 6,6-dimetilpiperidin-3-ilo, en donde uno o más átomos de hidrógeno en R³ se reemplazan en forma opcional por deuterio; y R⁴ es -CF₃ o cloro.Compositions including compounds of formula (1) or (1a), or forms thereof, and pharmaceutically acceptable salts, solvates (eg hydrates), stereoisomers, tautomers, and isotopic forms thereof. Also, methods (or uses) and kits, including pharmaceutically acceptable compounds or formulations, for treating or preventing a disease (eg, a proliferative disease) in a subject. Administration of a compound or pharmaceutical composition as described can inhibit the aberrant activity of cyclin-dependent kinase 7 (CDK7) and thus can induce cellular apoptosis in the subject. Claim 1: A compound having the structural formula (1), or a pharmaceutically acceptable salt thereof, wherein: R¹ is methyl or ethyl; R² is methyl or ethyl; R³ is 5-methylpiperidin-3-yl, 5,5-dimethylpiperidin-3-yl, 6-methylpiperdin-3-yl, or 6,6-dimethylpiperidin-3-yl, where one or more hydrogen atoms in R³ are optionally replaced by deuterium; and R⁴ is -CF₃ or chlorine.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862754398P | 2018-11-01 | 2018-11-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR116966A1 true AR116966A1 (en) | 2021-06-30 |
Family
ID=76972254
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP190103205A AR116966A1 (en) | 2018-11-01 | 2019-11-01 | CYCLINE-DEPENDENT KINASE INHIBITORS 7 (CDK7) |
Country Status (1)
| Country | Link |
|---|---|
| AR (1) | AR116966A1 (en) |
-
2019
- 2019-11-01 AR ARP190103205A patent/AR116966A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2021007230A2 (en) | Inhibitors of cyclin-dependent kinase 7 (cdk7) | |
| AR106252A2 (en) | PIRROLO COMPOUNDS [2,3-D] PYRIMIDINE | |
| DOP2018000187A (en) | DERIVATIVES OF PIRAZOLO [1,5-A] PIRAZIN-4-ILO | |
| AR114164A1 (en) | PYRIDOPYRIMIDINONES SUBSTITUTED WITH BENZYLAMINE AND DERIVATIVES AS INHIBITORS OF SOS1 | |
| AR111820A1 (en) | INDOLINA DERIVATIVES REPLACED AS INHIBITORS OF THE DENGUE VIRUS REPLICATION | |
| AR110400A1 (en) | AMINO-TRIAZOLOPIRIDINE COMPOUNDS AND THEIR USE IN CANCER TREATMENT | |
| AR108710A1 (en) | FXR MODULAR COMPOUNDS (NR1H4) | |
| AR089671A1 (en) | 1,4-DIHIDROPIRIMIDINAS 4,4-DISUSTITUIDAS AND ITS USE AS MEDICINES FOR THE TREATMENT OF HEPATITIS B | |
| AR111233A1 (en) | TYK2 INHIBITORS, USES AND METHODS FOR THE PRODUCTION OF THE SAME | |
| AR111314A1 (en) | INDOLINA DERIVATIVES REPLACED AS INHIBITORS OF THE DENGUE VIRIC REPLICATION | |
| PE20212303A1 (en) | AZA-HETEROBYCYCLIC MAT2A INHIBITORS AND METHODS OF USE IN THE TREATMENT OF CANCER | |
| AR111315A1 (en) | INDOLINA DERIVATIVES REPLACED AS INHIBITORS OF THE DENGUE VIRIC REPLICATION | |
| AR078157A1 (en) | DERIVATIVES OF PIRAZOL- [4,5-D] PIRROLO [2,3-B] PYRIDINE INHIBITORS OF JAK 2 THYROSINQUINASES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEMSELVES AND USE OF THE SAME IN THE TREATMENT OF CANCER | |
| AR093244A1 (en) | SUBSTITUTED BENZENE COMPOUNDS USED IN THE TREATMENT OF EZH2-DISORDERS | |
| AR110753A1 (en) | JAK1 SELECTIVE INHIBITORS | |
| AR108461A1 (en) | IMIDAZO COMPOUNDS [4,5-C] QUINOLIN-2-ONA AND ITS USE IN CANCER TREATMENT | |
| AR049578A1 (en) | HYDANTOIN DERIVATIVES, OBTAINING PROCESSES AND PHARMACEUTICAL COMPOSITIONS | |
| AR089143A1 (en) | SUBSTITUTED TRIAZOLOPIRIDINS WITH INHIBITING ACTIVITY OF TTK | |
| AR111494A1 (en) | ANILINOQUINAZOLINE C₅ COMPOUNDS AND ITS USE IN CANCER TREATMENT | |
| PE20211246A1 (en) | CYCLING COMPOUNDS FOR USE AS RIP1 KINASE INHIBITORS | |
| CL2020002550A1 (en) | Heteroaryl substituted pyrazole compounds and pharmaceutical use thereof. | |
| PE20181017A1 (en) | HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS | |
| AR096148A1 (en) | COMBINED THERAPY FOR TREATMENT OF CANCER | |
| UY29739A1 (en) | DERIVATIVES OF AMIDAS OR PHARMACEUTICALLY ACCEPTABLE SALTS OF THE SAME, PROCESSES OF PHARMACEUTICAL PREPARATIONS CONTAINING THEM AND APPLICATIONS | |
| PE20181895A1 (en) | CINNOLIN-4-AMINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER |